CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to GMAB

Epcoritamab

Phase 3
Genmab A/S (GMAB)

Phase 3

Development Phase

8

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Oct '27
GMABPhase 2

Epcoritamab Phase 2 Est. Readout

Epcoritamab
Oct 2027~
CT.gov
00%
Q3 '27
GMABPhase 2

Epcoritamab Phase 2 Est. Readout (EPCORE™ NHL-2)

Epcoritamab
Q3 2027~Q
CT.gov
00%
Sep '27
GMABPhase 2

Epcoritamab Phase 2 Est. Readout (EPCORE™ NHL-3)

Epcoritamab
Sep 2027~
CT.gov
00%
Q3 '27
GMABPhase 2

Epcoritamab Phase 2 Est. Readout

Epcoritamab
Q3 2027~Q
CT.gov
00%
Q3 '27
GMABPhase 2

Epcoritamab Phase 2 Est. Readout

Epcoritamab
Q3 2027~Q
CT.gov
00%
May '27
GMABPhase 2

Epcoritamab Phase 2 Est. Readout

Epcoritamab
May 2027~
CT.gov
00%
Apr '27
GMABPhase 2

Epcoritamab Phase 2 Est. Readout

Epcoritamab
Apr 2027~
CT.gov
00%
Mar '27
GMABPhase 2

Epcoritamab Phase 2 Est. Readout

Epcoritamab
Mar 2027~
CT.gov
00%
Competitive Landscape
Drug Information

Target Indication

Diffuse Large B-Cell Lymphoma

Clinical Trial

NCT05451810

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.